Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
published : This month tags : Europe crawled time : 11:00 save search
Positive Results from Phase 3 OPTIMIZE-1 Trial of Once Daily OCS-01 for the Treatment of Inflammation and Pain Following Cataract Surgery Presented at the 2024 American Society of Cataract and Refractive Surgery Annual Meeting
Published: 2024-04-08 (Crawled : 11:00) - biospace.com/
OCS 6 d | $11.84 -0.5% 43K
|
n/a
|
| O: 0.36%
H: 0.18%
C: -2.76%
ocs-01 positive treatment for meeting trial results
Innate Pharma Files Its 2023 Universal Registration Document (Document d’enregistrement Universel) and 2023 Annual Report on Form 20-F
Published: 2024-04-05 (Crawled : 11:00) - biospace.com/
SNYNF | News | $92.7 1.4K
|
Health Technology
|
| O: -1.77%
H: 0.0%
C: -1.81%
SNY | News | $45.445 -1.44% 2.6M
|
Health Technology
|
| O: -3.44%
H: 0.0%
C: 0.0%
IPHA | $2.41 11K
|
Health Technology
|
| O: -0.4%
H: 0.0%
C: -5.22%
pharma report universal
Gainers vs Losers
| 78% | 22% |
Top 10 Gainers
AGBA | $1.05 162.5% 100M
|
Finance
INVO | $1.36 78.95% 3.6M
|
Health Technology
BPTH | $5.62 73.46% 75M
|
Health Technology
TIRX | $0.8231 69.78% 54M
|
ISPC | $0.307 44.13% 3.6M
|
Professional, Scientific, and T...
SINT | $0.0519 39.14% 350M
|
Health Technology
XPON | $2.63 36.27% 8.4M
|
ALRN | $5.53 30.12% 250K
|
Health Technology
VTNR S | $1.26 28.68% 9.1M
|
Industrial Services
HOLO | $2.86 27.68% 28M
|
Your saved searches
Save your searches and get alerts when important news are released.